AAPS Open

Table 2 Summary of plasma pharmacokinetic parameters of JOTROL^TM (resveratrol) (PK population)

From: Safety and pharmacokinetics of a highly bioavailable resveratrol preparation (JOTROL ^TM)

		Treatment A				Treatment B
Analyte	Parameter (unit)	N	Mean	SD	CV%	N	Mean	SD	CV%
Resveratrol	AUC_0-t (h*ng/mL)	21	149	108	72	16	480	256	53
Plasma	AUC_0-inf (h*ng/mL)	1	215	-	-	5	574	325	57
	Residual Area (%)	1	5.48	-	-	5	5.55	4.08	74
	C_max (ng/mL)	21	127	116	91	16	455	409	90
	T_{1/2 el} (h)	1	1.26	-	-	5	2.74	1.71	63
	K_el (/h)	1	0.552	-	-	5	0.332	0.162	49
		Treatment A				Treatment B
Analyte	Parameter (unit)	N	Median	Min	Max	N	Median	Min	Max
Resveratrol	T_max (h)	21	0.999	0.25	2.01	16	1	0.496	2.001
		Treatment A				Treatment B
Analyte	Parameter (unit)	N	Mean	SD	CV%	N	Mean	SD	CV%
Urine	Ae0-t (ng)	21	22700	17100	75	16	54300	27100	50
	Rmax (ng/h)	21	12100	10000	82	16	39300	53700	137
	TRmax (h)	21	1.5	2.49	166	16	0.678	0.384	57
	CLR (L/h)	21	0.25	0.28	112	16	0.14	0.09	63
		Treatment C				Treatment D
Analyte	Parameter (unit)	N	Mean	SD	CV%	N	Mean	SD	CV%
Resveratrol	AUC_0-t (h*ng/mL)	18	886	456	52	14	306	201	66
Plasma	AUC_0-inf (h*ng/mL)	3	611	172	28	2	613	373	61
	Residual Area (%)	3	3.76	1.45	39	2	3.7	4.12	111
	C_max (ng/mL)	18	805	590	73	14	205	207	101
	T_{1/2 el} (h)	3	1.6	0.4	25	2	1.71	1.22	72
	K_el (/h)	3	0.455	0.13	29	2	0.547	0.392	72
		Treatment C				Treatment D
Analyte	Parameter (unit)	N	Median	Min	Max	N	Median	Min	Max
Resveratrol	T_max (h)	18	1.025	0.251	2	14	1.497	0.499	2.002
		Treatment C
Analyte	Parameter (unit)	N	Mean	SD	CV%
Urine	Ae0-t (ng)	18	143000	127000	88
	Rmax (ng/h)	18	63400	57700	91
	TRmax (h)	18	0.974	0.796	82
	CLR (L/h)	18	0.19	0.18	95

No urinary data collected in treatment D
N number of observations, SD standard deviation, CV coefficient of variation, Min minimum, Max maximum

Back to article page